Repeated treatment with a low dose of reserpine as a progressive model of Parkinson's disease

Behavioural Brain Research

Volumn 231, Issue 1, 2012, Pages 154-163

  Fernandes, Valéria S ^a   Santos, José R ^a   Leão, Anderson H F F ^a   Medeiros, André M ^a   Melo, Thieza G ^a   Izídio, Geison S ^a   Cabral, Alicia ^a   Ribeiro, Rosana A ^b   Abílio, Vanessa C ^b   Ribeiro, Alessandra M ^a   Silva, Regina H ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO NORTE   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Animal model; Memory; Movement disorders; Oxidative stress; Parkinson's disease; Reserpine

Indexed keywords

RESERPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AVOIDANCE BEHAVIOR; CATALEPSY; CONTROLLED STUDY; CORPUS STRIATUM; DISCRIMINATION LEARNING; DISEASE MODEL; HIPPOCAMPUS; LIPID PEROXIDATION; MALE; MEMORY DISORDER; MOTOR DYSFUNCTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; AVOIDANCE LEARNING; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; MALE; MOTOR ACTIVITY; PARKINSON DISEASE, SECONDARY; RATS; RECOGNITION (PSYCHOLOGY); RESERPINE;

EID: 84859175180     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2012.03.008     Document Type: Article

References (86)

1. Klockgether T. Parkinson's disease: clinical aspects. Cell Tissue Res 2004, 318:115-120.
2. Aarsland D., Andersen K., Larsen J.P., Perry R., Wentzel-Larsen T., Lolk A., et al. The rate of cognitive decline in Parkinson disease. Arch Neurol 2004, 61:1906-1911.
3. Mahieux F., Fénelon G., Flahault A., Manifacier M.J., Michelet D., Boller F. Neuropsychological prediction of dementia in Parkinson's disease. J Neurol Neurosurg Psychiatry 1998, 64:178-183.
4. Verbaan D., Marinus J., Visser M., van Rooden S.M.A., Stiggelbout M., Middelkoop H.A.M.J., et al. Cognitive impairment in Parkinson's disease. J Neurol Neurosurg Psychiatry 2007, 78:1182-1187.
5. Schmitt-Eliassen J., Ferstl R., Wiesner C., Deuschl G., Witt K. Feedback-based versus observational classification learning in healthy aging and Parkinson's disease. Brain Res 2007, 1142:178-188.
6. Cools R., Stefanova E., Barker R.A., Robbins T.W., Owen A.M. Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET. Brain 2002, 125:584-594.
7. Cox S.M.L., Stefanova E., Johnsrude I.S., Robbins T.W., Owen A.M. Preference formation and working memory in Parkinson's disease and normal ageing. Neuropsychologia 2002, 40:317-326.
8. Morris R.G., Downes J.J., Sahakian B.J., Evenden J.L., Heald A., Robbinsii T.W. Planning and spatial working memory in Parkinson's disease. J Neurol Neurosurg Psychiatry 1988, 51:757-766.
9. Bronnick K., Ehrt U., Emre M., De Deyn P.P., Wesnes K., Tekin S., et al. Attentional deficits affect activities of daily living in dementia-associated with Parkinson's disease. J Neurol Neurosurg Psychiatry 2006, 77:1136-1142.
10. Beal M.F. Experimental models of Parkinson's disease. Nat Rev Neurosci 2001, 2:325-332.
11. Bellissimo M.I., Kouzmine I., Ferro M.M., de Oliveira B.H, Canteras N.S., Da Cunha C. Is the unilateral lesion of the left substantia nigra pars compacta sufficient to induce working memory impairment in rats. Neurobiol Learn Mem 2004, 82:150-158.
12. Da Cunha C., Angelucci M.E.M., Canteras N.S., Wonnacott S., Takahashi R.N. The lesion of the rat substantia nigra pars compacta dopaminergic neurons as a model for Parkinson's disease memory disabilities. Cell Mol Neurobiol 2002, 22:227-237.
13. Henderson J.M., Stanic D., Tomas D., Patch J., Horne M.K., Bourke D., et al. Postural changes after lesions of the substantia nigra pars reticulata in hemiparkinsonian monkeys. Behav Brain Res 2005, 160:267-276.
14. Colpaert F.C. Pharmacological characteristics of tremor, rigidity and hypokinesia induced by reserpine in rat. Neuropharmacology 1987, 26:1431-1440.
15. Gerlach M., Riederer P. Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J Neural Transm 1996, 103:987-1041.
16. Dutra R.C., Andreazza A.P., Andreatini R., Tufik S. Vital MABF. Behavioral effects of MK-801 on reserpine-treated mice. Prog Neuropsychopharmacol Biol Psychiatry 2002, 26:487-495.
17. Shiozaki S., Ichikawa S., Kitamura J.N.S., Yamada K., Kuwana Y. Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology 1999, 147:90-95.
18. Faria R.R., Abílio V.C., Grassl C., Chinen C.C., Negrão L.T.R., de Castro J.P.M.V., et al. Beneficial effects of vitamin C and vitamin E on reserpine-induced oral dyskinesia in rats: critical role of striatal catalase activity. Neuropharmacology 2005, 48:993-1001.
19. Peixoto M.F., Araujo N.P., Silva R.H., Castro J.P.M.V., Fukushiro D.F., Faria R.R., et al. Effects of gabaergic drugs on reserpine-induced oral dyskinesia. Behav Brain Res 2005, 160:51-59.
20. Tadaiesky M.T., Andreatini R. Vital MABF. Different effects of 7-nitroindazole in reserpine-induced hypolocomotion in two strains of mice. Eur J Pharmacol 2006, 535:199-207.
21. Carvalho R.C., Patti C.C., Takatsu-Coleman A.L., Kameda S.R., Souza C.F., Garcez-do-Carmo L. Effects of reserpine on the plus-maze discriminative avoidance task: dissociation between memory and motor impairments. Brain Res 2006, 1122:176-183.
22. Fernandes V.S., Ribeiro A.M., Melo T.G., Godinho M., Barbosa F.F., Medeiros D.S., et al. Memory impairment induced by low doses of reserpine in rats: possible relationship with emotional processing deficits in Parkinson disease. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1479-1483.
23. Bowers D., Miller K., Mikos A., Kirsch-Darrow L., Springer U., Fernandez H., et al. Startling facts about emotion in Parkinson's disease: blunted reactivity to aversive stimuli. Brain 2006, 129:3356-3365.
24. Salgado-Pineda P., Delaveau P., Blin O., Nieoullon A. Dopaminergic contribution to the regulation of emotional perception. Clin Neuropharmacol 2005, 28:228-237.
25. Schneider K., Habel U., Volkmann J., Regel S., Kornischka J., Sturm V., et al. Deep brain stimulation of the subthalamic nucleus enhances emotional processing in Parkinson disease. Arch Gen Psychiatry 2003, 60:296-302.
26. Caudle W.M., Colebrooke R.E., Emson P.C., Miller G.W. Altered vesicular dopamine storage in Parkinson's disease: a premature demise. Trends Neurosci 2008, 31:303-308.
27. Tsang A.H.K., Chung K.K.K. Oxidative and nitrosative stress in Parkinson's disease. Biochim Biophys Acta 2009, 1792:643-650.
28. Lohr J.B. Oxygen radicals and neuropsychiatric illness. Some speculations. Arch Gen Psychiatry 1991, 48:1097-1106.
29. Dröge W. Free radicals in the physiological control of cell function. Physiol Rev 2002, 82(1):47-95.
30. Teixeira A.M., Reckziegel P., Müller L., Pereira R.P., Roos D.H., Rocha J.B.T., et al. Intense exercise potentiates oxidative stress in striatum of reserpine-treated animals. Pharmacol Biochem Behav 2009, 92:231-235.
31. Chen Q., Niu Y., Zhang R., Guo H., Gao Y., Li Y., et al. The toxic influence of paraquat on hippocampus of mice: involvement of oxidative stress. Neurotoxicology 2010, 31:310-316.
32. Beal M.F. Mitochondria, oxidative damage, and inflammation in Parkinson's disease. Ann NY Acad Sci 2003, 991:120-131.
33. Cadenas E., Davies K.J.A. Mitochondrial free radical generation, oxidative stress, and aging. Free Radic Biol Med 2000, 29:222-230.
34. Beal M.F. Oxidatively modified proteins in aging and disease. Free Radic Biol Med 2002, 32:797-803.
35. Obata T. Dopamine efflux by MPTP and hydroxyl radical generation. J Neural Transm 2002, 109:1159-1180.
36. Riobó N.A., Schopfer F.J., Boveris A.D., Cadenas E., Poderoso J.J. The reaction of nitric oxide with 6-hydroxydopamine: implications for Parkinson's disease. Free Radic Biol Med 2002, 32:115-121.
37. Bilska A., Dubiel M., Sokolowska-Jezewicz M., Lorenc-Koci E., Wlodek L. Alpha-lipoic acid differently affects the reserpine-induced oxidative stress in the striatum and prefrontal cortex o rat brain. Neuroscience 2007, 146:1758-1771.
38. Spina M.B., Cohen G. Dopamine turnover and glutathione oxidation: implications for Parkinson disease. Proc Natl Acad Sci USA 1989, 86:1398-1400.
39. Silva R.H., Frussa-Filho R. The plus-maze discriminative avoidance task: a new model to study memory-anxiety interactions. Effects of chlordiazepoxide and caffeine. J Neurosci Methods 2000, 102:117-125.
40. Ribeiro A.M., Barbosa F.F., Godinho M.R., Fernandes V.S., Munguba H., Melo T.G., et al. Sex differences in aversive memory in rats: possible role of extinction and reactive emotional factors. Brain Cogn 2010, 74:145-151.
41. Tanizawa H., Sazuka Y., Tabino Y. Micro-determination of lipoperoxide inthe mouse myocardium by thiobarbituric acid fluorophotometry. Chem Pharm Bull (Tokyo) 1981, 29:2910-2914.
42. Johnston R.E., Schallert T., Becker J.B.B. Akinesia and postural abnormality after unilateral dopamine depletion. Behav Brain Res 1999, 104:189-196.
43. Lindner M.D., Cain C.K., Plone M.A., Frydel B.R., Blaney T.J., Emerich D.F., et al. Incomplete nigrostriatal dopaminergic cell loss and partial reductions in striatal dopamine produce akinesia, rigidity, tremor and cognitive deficits in middle-aged rats. Behav Brain Res 1999, 102:1-16.
44. Ridley R.M., Cummings R.M., Leow-Dyke A., Baker H.F. Neglect of memory after dopaminergic lesions in monkeys. Behav Brain Res 2006, 166:253-262.
45. Mayeux R. Epidemiology of neurodegeneration. Annu Rev Neurosci 2003, 26:81-104.
46. Chinen C.C., Frussa-Filho R. Conditioning to injection procedures and repeated testing increase SCH 23390-induced catalepsy in mice. Neuropsychopharmacology 1999, 21:670-678.
47. Diaz M.R., Abdala P., Barroso-Chinea P., Obeso J., Gonzalez-Hernande T. Motor behavioural changes after intracerebroventricular injection of 6-hydroxydopamine in the rat: an animal model of Parkinson's disease. Behav Brain Res 2001, 122:79-92.
48. Góngora-Alfaro J.L., Moo-Puc R.E., Villanueva-Toledo J.R., Alvarez-Cervera F.J., Bata-García J.L., Heredia-López F.J., et al. Long-lasting resistance to haloperidol-induced catalepsy in male rats chronically treated with caffeine. Neurosci Lett 2009, 463:210-214.
49. Corona J.C., Gimenez-Cassina A., Lim F., Díaz-Nido J. Hexokinase II gene transfer protects against neurodegeneration in the rotenone and MPTP mouse models of Parkinson's disease. J Neurosci Res 2010, 88:1943-1950.
50. Amtage J., Schmidt W.J. Context-dependent catalepsy intensification is due to classical conditioning and sensitization. Behav Pharmacol 2003, 14:563-567.
51. Frank S.T., Schmidt W.J. Increase of spiny I activity in striatum after development of context-dependent sensitization of catalepsy in rats. Neurosci Lett 2004, 354:10-13.
52. Delfino M.A., Stefano A.V., Ferrario J.E., Tavavini I.R.E., Murer M.G., Gershanik O.S. Behavioral sensitization to different dopamine agonists in a Parkinsonian rodent model of drug-induced dyskinesias. Behav Brain Res 2004, 152:297-306.
53. Ferro M.M., Bellissimo M.I., Anselmo-Franci J.á., Angellucci M.E.M., Canteras N.S., Da Cunha C. Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson's disease: histological, neurochemical, motor and memory alterations. J Neurosc Methods 2005, 148:78-87.
54. Capitelli C., Sereniki A., Lima M.M.S., Reksidler A.B., Tufik S., Vital M.A.B.F. Melatonin attenuates tyrosine hydroxylase loss and hypolocomotion in MPTP-lesioned rats. Eur J Pharmacol 2008, 594:101-108.
55. Abílio V.C., Araujo C.C.S., Bergamo M., Calvente P.R.V., D'Almeida V., de A.R.R. Vitamin E attenuates reserpine-induced oral dyskinesia and striatal gssg/gsh ratio enhancement in rats. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27:109-114.
56. Abílio V.C., Silva R.H., Carvalho R.C., Grassl C., Calzavara M.B., Registro S. Important role of striatal catalase in aging- and reserpine-induced oral dyskinesia. Neuropharmacology 2004, 47:263-272.
57. Neisewander J.L., Lucki I., McGonigle P. Neurochemical changes associated with the persistence of spontaneous oral dyskinesia in rats following chronic reserpine treatment. Brain Res 1991, 558:27-35.
58. Neisewander J.L., Castañeda E., Davis D.A. Dose-dependent differences in the development of reserpine-induced oral dyskinesia in rats: support for a model of tardive dyskinesia. Psychopharmacology 1994, 116:79-84.
59. Andreassen O.A., Jorgensen H.A. Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia. Prog Neurobiol 2000, 61:525-541.
60. Hansen E., Casey D.E., Hoffma W.F. Neuroleptic intolerance. Schizophr Bull 1997, 23:567-582.
61. Salamone J., Baskin P. Vacuous jaw movements Induced by acute reserpine and low-dose apomorphine: possible model of Parkinsonian tremor. Pharmacol Biochem Behav 1996, 53:179-183.
62. Salamone J.D., Ishiwari K., Betz A.J., Farrar A.M., Mingote S.M., Font L., et al. Dopamine/adenosine interactions related to locomotion and tremor in animal models: possible relevance to Parkinsonism. Parkinsonism Relat Disord 2008, 14:S130-S134.
63. Andreassen O.A., Ferrante R.J., Aamo T.O., Bealf M.F., Jorgensen H.A. Oral dyskinesia and histopathological alterations in substantia nigra after long-term haloperidol treatment of old rats. Neuroscience 2003, 122:717-725.
64. Jicha G.A., Salamone J.D. Vacuous jaw movements and feeding deficits in rats with ventrolateral striatal dopamine depletion: possible relation to Parkinsonian symptoms. J Neurosci 1991, 12:3822-3929.
65. Robertson L.T., Horak F.B., Anderson V.C., Burchiel K.J., Hammerstad J.P. Assessments of axial motor control during deep brain stimulation in Parkinsonian patients. Neurosurgery 2001, 48:544-552.
66. Sussman A.N., Tran-Nguyen L.T.L., Neisewander J.L. Acute reserpine administration elicits long-term spontaneous oral dyskinesia. Eur J Pharmacol 1997, 337:157-160.
67. Higginson C.I., Fields J.A., Troster A.I. Which symptoms of anxiety diminish after surgical interventions for Parkinson disease?. Neuropsychiatry Neuropsychol Behav Neurol 2001, 14:117-121.
68. Koerts J., Leenders K.L., Koning M., Portman A.T., Beilen N.V. Striatal dopaminergic activity (FDOPA-PET) associated with cognitive items of depression scale (MADRS) in Parkinson's disease. Eur J Neurosci 2007, 25:3132-3136.
69. Korczyn A.D. Dementia in Parkinson's disease. J Neurol 2001, 248(Suppl. 3):1-4.
70. Zgaljardic D.J., Foldi N.S., Borod J.C. Cognitive and behavioral dysfunction in Parkinson's disease: neurochemical and clinicopathogical contributions. J Neural Transm 2004, 111:1287-1301.
71. Gabrieli J.D.E. Memory systems analyses of mnemonic disorders in aging and age-related diseases. Proc Natl Acad Sci USA 1996, 93:13534-13540.
72. Postle B.R., Locascio J.J., Corkin S., Growdon J.H. The time course of spatial and object learning in Parkinson's disease. Neuropsychologia 1997, 35:1413-1422.
73. Silva R.H., Abílio V.C., Torres-Leite D., Bergamo M., Chinen C.C., Claro F.T., et al. Concomitant development of oral dyskinesia and memory deficits in reserpine-treated male and female mice. Behav Brain Res 2002, 132:171-177.
74. Kameda S.R., Frussa-Filho R., Carvalho R.C., Takatsu-Coleman A.L., Ricardo V.P., Patti C.L., et al. Dissociation of the effects of ethanol on memory, anxiety, and motor behavior in mice tested in the plus-maze discriminative avoidance task. Psychopharmacology 2007, 192:39-48.
75. Silva R.H., Kameda S.R., Carvalho R.C., Rigo G.S., Costa K.L.B., Taricano I.D., et al. Effects of amphetamine on the plus-maze discriminative avoidance task in mice. Psychopharmacology 2002, 160:9-18.
76. Niigaki S.T., Silva R.H., Patti C.L., Cunha J.L.S., Kameda S.R., Correia-Pinto J.C., et al. Amnestic effect of cocaine after the termination of its stimulant action. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:212-218.
77. Halbig T.D., Kopp U.A., Wodarz F., Borod J.C., Gracies J.M., Ebersbach G., et al. Dopaminergic modulation of emotional memory in Parkinson's disease. J Neural Transm 2008, 115:1159-1163.
78. Bezard E., Dovero S., Prunier C., Ravenscroft P., Chalon S., Guilloteau D., et al. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J Neurosci 2001, 21:6853-6861.
79. Bezard E., Gross C.E. Compensatory mechanisms in experimental and human Parkinsonism: towards a dynamic approach. Prog Neurobiol 1998, 55:93-116.
80. Castaneda E., Whishaw I.Q., Robinson T.E. Changes in striatal dopamine neurotransmission assessed with microdialysis following recovery from a bilateral 6-OHDA lesion: variation as a function of lesion size. J Neurosci 1990, 10:1847-1854.
81. Cropley V.L., Fujita M., Innis R.B., Nathan P.J. Molecular imaging of the dopaminergic system and its association with human cognitive function. Biol Psychiatry 2006, 59:898-907.
82. Borah A., Mohanakumar K.P. Long-term l-DOPA treatment causes indiscriminate increase in dopamine levels at the cost of serotonin synthesis in discrete brain regions of rats. Cell Mol Neurobiol 2007, 27:985-996.
83. Ossowska K., Konieczny J., Wardas J., Golémbiowska K., Wolfarth S., Pilc A. The role of striatal metabotropic glutamate receptors in Parkinson's disease. Amino Acids 2002, 23:193-198.
84. Caudle W.M., Richardson J.R., Wang M.Z., Taylor T.N., Guillot T.S., McCormack A.L., et al. Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. J Neurosci 2007, 27:8138-8148.
85. Taylor T.N., Caudle W.M., Shepherd K.R., Noorian A., Jackson C.R., Iuvone P.M., et al. Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity. J Neurosci 2009, 29:8103-8113.
86. Miller G.W., Erickson J.D., Perez J.T., Penland S.N., Mash D.C., Rye D.B., et al. Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease. Exp Neurol 1999, 156:138-148.